Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors.
Journal: 2006/June - Annals of Surgery
ISSN: 0003-4932
Abstract:
OBJECTIVE
Gastric gastrointestinal stromal tumors (GISTs) are rare neoplasms that require excision for cure. Although the feasibility of minimally invasive resection of gastric GIST has been established, the long-term safety and efficacy of these techniques are unclear. We hypothesized that complete resection of gastric GISTs using a combination of laparoscopic or laparoendoscopic techniques results in low perioperative morbidity and an effective long-term control of the disease.
METHODS
Between August 1996 and June 2005, 50 consecutive patients undergoing laparoscopic or laparoendoscopic resection of gastric GISTs were identified in a prospectively collected database. Outcome measures included patient demographics and outcomes, operative findings, morbidity, and histopathologic characteristics of the tumor. Patient and tumor characteristics were analyzed to identify risk factors for tumor recurrence.
RESULTS
Fifty patients, mean age 60 years (range, 34-84 years), underwent 47 local and 3 segmental laparoscopic gastric resections. GI bleeding and dyspepsia were the most common symptoms. Mean tumor size was 4.4 cm (range, 1.0-8.5 cm) with the majority of the lesions located in the proximal stomach. Mean operative time was 135 minutes (range, 49-295 minutes), the mean blood loss was 85 mL (range, 10-450 mL), and the mean length of hospitalization was 3.8 days (range 1-10 days). There were no major perioperative complications or mortalities. All lesions had negative resection margins (range, 2-45 mm). Nine patients had 10 or more mitotic figures per 50 high power fields, while 11 had ulceration and/or necrosis of the lesion. At a mean follow-up of 36 months, 46 (92%) patients were disease free, 1 patient was alive with disease, 1 patient with metastases died of a cardiac event, and 2 (4%) patients died of metastatic disease. No local or port site recurrences have been identified. Patient age, tumor size, mitotic index, tumor ulceration, and necrosis were statistically associated with tumor recurrence. The presence of 10 or more mitotic figures per 50 high power fields was an independent predictor of disease progression (P = 0.006).
CONCLUSIONS
A laparoscopic approach to surgical resection of gastric GIST is associated with low morbidity and short hospitalization. As found in historical series of open operative resection, the tumor mitotic index predicts local recurrence. The long-term disease-free survival of 92% in our study establishes laparoscopic resection as safe and effective in treating gastric GISTs. Given these findings as well as the advantages afforded by minimally invasive surgery, a laparoscopic approach may be the preferred resection technique in most patients with small- and medium-sized gastric GISTs.
Relations:
Content
Citations
(120)
References
(34)
Diseases
(1)
Organisms
(1)
Processes
(1)
Affiliates
(1)
Similar articles
Articles by the same authors
Discussion board
Ann Surg 243(6): 738-747

Long-term Outcomes of Laparoscopic Resection of Gastric Gastrointestinal Stromal Tumors

From the Division of Gastrointestinal and Minimally Invasive Surgery, Department of Surgery, Carolinas Medical Center, Charlotte, NC.

Abstract

Objective:

Gastric gastrointestinal stromal tumors (GISTs) are rare neoplasms that require excision for cure. Although the feasibility of minimally invasive resection of gastric GIST has been established, the long-term safety and efficacy of these techniques are unclear. We hypothesized that complete resection of gastric GISTs using a combination of laparoscopic or laparoendoscopic techniques results in low perioperative morbidity and an effective long-term control of the disease.

Methods:

Between August 1996 and June 2005, 50 consecutive patients undergoing laparoscopic or laparoendoscopic resection of gastric GISTs were identified in a prospectively collected database. Outcome measures included patient demographics and outcomes, operative findings, morbidity, and histopathologic characteristics of the tumor. Patient and tumor characteristics were analyzed to identify risk factors for tumor recurrence.

Results:

Fifty patients, mean age 60 years (range, 34–84 years), underwent 47 local and 3 segmental laparoscopic gastric resections. GI bleeding and dyspepsia were the most common symptoms. Mean tumor size was 4.4 cm (range, 1.0–8.5 cm) with the majority of the lesions located in the proximal stomach. Mean operative time was 135 minutes (range, 49–295 minutes), the mean blood loss was 85 mL (range, 10–450 mL), and the mean length of hospitalization was 3.8 days (range 1–10 days). There were no major perioperative complications or mortalities. All lesions had negative resection margins (range, 2–45 mm). Nine patients had 10 or more mitotic figures per 50 high power fields, while 11 had ulceration and/or necrosis of the lesion. At a mean follow-up of 36 months, 46 (92%) patients were disease free, 1 patient was alive with disease, 1 patient with metastases died of a cardiac event, and 2 (4%) patients died of metastatic disease. No local or port site recurrences have been identified. Patient age, tumor size, mitotic index, tumor ulceration, and necrosis were statistically associated with tumor recurrence. The presence of 10 or more mitotic figures per 50 high power fields was an independent predictor of disease progression (P = 0.006).

Conclusion:

A laparoscopic approach to surgical resection of gastric GIST is associated with low morbidity and short hospitalization. As found in historical series of open operative resection, the tumor mitotic index predicts local recurrence. The long-term disease-free survival of 92% in our study establishes laparoscopic resection as safe and effective in treating gastric GISTs. Given these findings as well as the advantages afforded by minimally invasive surgery, a laparoscopic approach may be the preferred resection technique in most patients with small- and medium-sized gastric GISTs.

Abstract

Footnotes

Reprints: B. Todd Heniford, MD, FACS, Division of Gastrointestinal and Minimally Invasive Surgery, Department of Surgery, Carolinas Medical Center, 1000 Blythe Blvd, MEB 601, Charlotte, NC, 28203. E-mail: gro.erachtlaehsanilorac@drofineh.ddot.

Footnotes

REFERENCES

REFERENCES

References

  • 1. Corless CL, Fletcher JA, Heinrich MCBiology of gastrointestinal stromal tumors. J Clin Oncol. 2004;22:3813–3825. [[PubMed]
  • 2. DeMatteo RP, Lewis JJ, Leung D, et alTwo hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival. Ann Surg. 2000;231:51–58.
  • 3. Nowain A, Bhakta H, Pais S, et alGastrointestinal stromal tumors: clinical profile, pathogenesis, treatment strategies and prognosis. J Gastroenterol Hepatol. 2005;20:818–824. [[PubMed]
  • 4. Graadt van Roggen JF, van Velthuysen ML, Hogendoorn PCThe histopathological differential diagnosis of gastrointestinal stromal tumours. J Clin Pathol. 2001;54:96–102.
  • 5. Fletcher CD, Berman JJ, Corless C, et alDiagnosis of gastrointestinal stromal tumors: a consensus approach. Hum Pathol. 2002;33:459–465. [[PubMed]
  • 6. Miettinen M, Virolainen M, Maarit Sarlomo RGastrointestinal stromal tumors: value of CD34 antigen in their identification and separation from true leiomyomas and schwannomas. Am J Surg Pathol. 1995;19:207–216. [[PubMed]
  • 7. Sarlomo-Rikala M, Kovatich AJ, Barusevicius A, et alCD117: a sensitive marker for gastrointestinal stromal tumors that is more specific than CD34. Mod Pathol. 1998;11:728–734. [[PubMed]
  • 8. Kindblom LG, Remotti HE, Aldenborg F, et alGastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal. Am J Pathol. 1998;152:1259–1269.
  • 9. Miettinen M, Sobin LH, Lasota JGastrointestinal stromal tumors of the stomach: a clinicopathologic, immunohistochemical, and molecular genetic study of 1765 cases with long-term follow-up. Am J Surg Pathol. 2005;29:52–68. [[PubMed]
  • 10. Heinrich MC, Corless CLGastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy. J Surg Oncol. 2005;90:195–207; discussion 207. [[PubMed]
  • 11. Cheng HL, Lee WJ, Lai IR, et alLaparoscopic wedge resection of benign gastric tumor. Hepatogastroenterology. 1999;46:2100–2104. [[PubMed]
  • 12. Matthews BD, Walsh RM, Kercher KW, et alLaparoscopic vs open resection of gastric stromal tumors. Surg Endosc. 2002;16:803–807. [[PubMed]
  • 13. Cuschieri ALaparoscopic gastric resection. Surg Clin North Am. 2000;80:1269–1284. [[PubMed]
  • 14. Matthews BD, Joels CS, Kercher KW, et alGastrointestinal stromal tumors of the stomach. Minerva Chir. 2004;59:219–231. [[PubMed]
  • 15. Heniford BT, Arca MJ, Walsh RMThe mini-laparoscopic intragastric resection of a gastroesophageal stromal tumor: a novel approach. Surg Laparosc Endosc Percutan Tech. 2000;10:82–85. [[PubMed]
  • 16. Walsh RM, Ponsky J, Brody F, et alCombined endoscopic/laparoscopic intragastric resection of gastric stromal tumors. J Gastrointest Surg. 2003;7:386–392. [[PubMed]
  • 17. Geis WP, Baxt R, Kim HCBenign gastric tumors: minimally invasive approach. Surg Endosc. 1996;10:407–410. [[PubMed]
  • 18. Nguyen NT, Jim J, Nguyen A, et alLaparoscopic resection of gastric stromal tumor: a tailored approach. Am Surg. 2003;69:946–950. [[PubMed]
  • 19. Demetri GD, Blanke CD. NCCN Task Force Report. Optimal management of patients with gastrointestinal stromal tumors (GIST): expansion and update of NCCN Clinical Guidelines. J Natl Comp Cancer Network. 2004;2(suppl):1–26. [[PubMed]
  • 20. Fujimoto Y, Nakanishi Y, Yoshimura K, et alClinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: analysis of results in 140 surgically resected patients. Gastric Cancer. 2003;6:39–48. [[PubMed]
  • 21. Blanke CD, Corless CLState-of-the art therapy for gastrointestinal stromal tumors. Cancer Invest. 2005;23:274–280. [[PubMed]
  • 22. Nickl NJGastrointestinal stromal tumors: new progress, new questions. Curr Opin Gastroenterol. 2004;20:482–487. [[PubMed]
  • 23. Chak A, Canto MI, Rosch T, et alEndosonographic differentiation of benign and malignant stromal cell tumors. Gastrointest Endosc. 1997;45:468–473. [[PubMed]
  • 24. Mazur MT, Clark HBGastric stromal tumors: reappraisal of histogenesis. Am J Surg Pathol. 1983;7:507–519. [[PubMed]
  • 25. Ernst SI, Hubbs AE, Przygodzki RM, et alKIT mutation portends poor prognosis in gastrointestinal stromal/smooth muscle tumors. Lab Invest. 1998;78:1633–1636. [[PubMed]
  • 26. Chou FF, Eng HL, Sheen-Chen SMSmooth muscle tumors of the gastrointestinal tract: analysis of prognostic factors. Surgery. 1996;119:171–167. [[PubMed]
  • 27. Rosen MJ, Heniford BTEndoluminal gastric surgery: the modern era of minimally invasive surgery. Surg Clin North Am. 2005;85:989–1007. [[PubMed]
  • 28. Yoshida M, Otani Y, Ohgami M, et alSurgical management of gastric leiomyosarcoma: evaluation of the propriety of laparoscopic wedge resection. World J Surg. 1997;21:440–443. [[PubMed]
  • 29. Ng EH, Pollock RE, Munsell MF, et alPrognostic factors influencing survival in gastrointestinal leiomyosarcomas: implications for surgical management and staging. Ann Surg. 1992;215:68–77.
  • 30. A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med. 2004;350:2050–2059. [[PubMed]
  • 31. Rassweiler J, Tsivian A, Kumar AV, et alOncological safety of laparoscopic surgery for urological malignancy: experience with more than 1,000 operations. J Urol. 2003;169:2072–2075. [[PubMed]
  • 32. Gigot JF, Glineur D, Santiago Azagra J, et alLaparoscopic liver resection for malignant liver tumors: preliminary results of a multicenter European study. Ann Surg. 2002;236:90–97.
  • 33. Tazawa K, Tsukada K, Makuuchi H, et alAn immunohistochemical and clinicopathological study of gastrointestinal stromal tumors. Pathol Int. 1999;49:786–798. [[PubMed]
  • 34. Evans HLSmooth muscle tumors of the gastrointestinal tract: a study of 56 cases followed for a minimum of 10 years. Cancer. 1985;56:2242–2250. [[PubMed]
Collaboration tool especially designed for Life Science professionals.Drag-and-drop any entity to your messages.